CD8A and Miyoshi myopathy: The median percentage of virus-specific CD8+ T cells detected in MM patients after the second dose was similar to that of B-CLPD and HCP (0.20%, 0.20%, and 0.18% among CD8+ T cells, respectively; P ≥ 0.71 for all comparisons) (Fig. 3E).